The White House budget
proposal, released earlier this month, includes a requirement for
pharmaceutical companies to disclose various business measures, including the
cost of research and development; a requirement that would either prove or lay
to rest to pharma’s continued argument that drug prices are directly related to
their R&D costs. The measures mimic those proposed by states across the
country and received similar backlash from industry lobbyists – including
assertions that the requirement would stifle innovation, ignores R&D
failures, and requires the disclosure of confidential information. That final
argument is likely countered by an existing statute in the Affordable Care Act.
Read the coverage from Pharmalot's Ed Silverman here.
